# Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

> **NCT03570827** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 52 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage IIB Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Androgen Suppression
- **RADIATION:** Hypofractionated Radiation Therapy
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03570827
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-14
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03570827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03570827, "Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03570827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*